




# TIL for the Treatment of Patients with Solid Cancer An Interactive Workshop



Personalized T-cell therapy has now reached the solid tumor therapy field as a first-of-its-kind immunotherapy for patients with melanoma with an approval granted by the FDA on February 17<sup>th</sup> 2024

## Target group

Experts from science, industry and authorities involved in development, regulation and marketing of TIL or other T-cell based (transgenic) therapeutic products. Physicians involved in cell-based immunotherapy and immunotherapy. Individuals involved in TIL manufacturing and other transgenic immune cell products. We aim to provide a nurturing environment for cross-fertilizing discussions in science, cell therapy development and regulatory requirements.



## Program

**Wednesday 24<sup>th</sup> April 2024**  
**09:00h- 18:30h**

### Welcome

Leonor Beleza, João Silveira Botelho

### Cellular immunotherapy and TIL – history of development and a future foretold

Michael T. Lotze, Departments of Surgery, Immunology, and Bioengineering, University of Pittsburgh Medical Center, Pittsburgh, USA

### TIL for patients with solid cancer

Markus Maeurer, Champalimaud Foundation, Lisbon, Portugal

### Losing it all – the case for functional MHC expression testing: prerequisites for cell therapy

Barbara Seliger, Translational Immunology MHB Fontane Brandenburg, Brandenburg, Germany

### TCR gamma-delta – T-cells for immunotherapy of epithelial cancers

Dieter Kabelitz, UKSH Institute Immunology, University of Kiel, Kiel, Germany

Moderated discussion

## Lunch break sponsored by Lonza

**13:00 - 14:30 h**

### *Presentation of the Lonza Cocoon System*

### Clonal neoantigens as key targets for TIL therapy in non-small cell lung cancer

Sergio Quezada, University College London and Achilles London, UK

### Clonotypes dynamic and specificity as correlates of efficacy of TIL therapy

Alexandre Harari, Ludwig Institute for Cancer Research, Lausanne, Switzerland

### The other side of T-cell therapy: private mutations - peptide cancer vaccination

Saskia Biskup, CeGaT & University of Tuebingen, Tuebingen, Germany

## Coffee break

### Interaction of TIL with the TME – good or bad?

Elfriede Noessner, Helmholtz Center, Munich, Germany

### From Vision to Reality: building a GMP facility

Cristina Afonso, Bernardo Marineiro, Nuno Pereira, Joaquim Teixeira, Champalimaud Foundation & Peter Christian Rehm, Hans-Georg Eckert, Syntegon/Valicare

### ATMP regulations

Infarmed, Portugal, *to be named* and Paul Ehrlich Institute, Ralf Sanzenbacher, Germany

Possibility to visit the GMP Facility



# TIL for the Treatment of Patients with Solid Cancer

## An Interactive Workshop



**Thursday, 25<sup>th</sup> April 2024**  
**09:00h-18:30h**

**TIL – treatment for patients with melanoma. Clinical experience and future directions**

Guy Ben-Betzalel, Ella Lemelbaum  
Institute for Immuno- Oncology. Sheba  
Clinic, Tel HaShomer, Israel

**Managing Exhaustion and T-cell fitness: Lessons from CAR-T-cell therapies**

Orit Itzhaki, Sheba-Clinical Center, Tel  
HaShomer, Israel

### **Coffee Break**

**A tale of tribulations and trials: developing a cell therapy program in Europe**

Lana Kandalajt, Chief of Service of the GMP  
facility - Ludwig Institute for Cancer  
Research, Lausanne, Switzerland

**TIL characterization by flow cytometry**  
Michael Kapinsky, Beckman Coulter

**ATMP process risk analysis and validation**  
Hans-Georg Eckert, Valicare

**Lunch break sponsored by  
Wilson Wolf Corporation 13.00-14.30**

*Presentation of G-Rex, Cell Ready  
System, Wilson Wolf Corp*

**Decentralized autologous cell therapy  
manufacturing at the point of care -  
advantages of harmonized tils  
manufacturing in an OMPUL™  
(Orgenesis Mobile Processing Units and  
Labs™)**

Moran Meiron, Orgenesis

**How to tackle regional differences in CMC  
requirements for a global clinical/  
commercial development**

Robert Zoubek, Granzer

**Cell therapies come of age –  
balance of efficacy and safety:  
lessons from CAR-T-cell trials**

Michael Bachmann, Helmholtz-Zentrum  
Dresden- Rossendorf (HZDR) and  
German Cancer Consortium (DKTK),  
Dresden and German Cancer Research  
Center (DKFZ), Heidelberg, Germany

- Access for students, academics and authorities is free

Industry: participation fee 200 euro

- **Registration:** <https://www.eventbrite.com/e/til-for-the-treatment-of-patients-with-solid-cancer-tickets-869620146267>

- **Location**

Exhibition Hall


Champalimaud Foundation

Avenida Brasília 1400-038

Lisboa Portugal

Phone: + 351 210 480 200

mail: [info@fundacaochampalimaud.pt](mailto:info@fundacaochampalimaud.pt)



**Welcome to an inclusive, interactive  
TIL workshop in Lisbon 24/25 April !**